Zydus Nesher Pharmaceuticals gets FDA nod for antifungal drug
New Delhi: Zydus Group firm Cadila Healthcare said its subsidiary Nesher Pharmaceuticals has received nod from the USFDA to market Nystatin topical powder used for treating skin infections in the US market.
"Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the United States Food and Drug Administration to market Nystatin topical powder USP 100,000 units per gram", Cadila Healthcare said in a BSE filing.
The drug will be produced at Nesher Pharmaceuticals manufacturing facility in USA, it added.
"The group has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of filing process...", it added.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd